Customer Experience Seal of Satisfaction


As the world leader in the manufacturing and sale of dental anesthetics and the makers of Septocaine, the #1 brand in dental anesthetics in the US, Septodont offers a Customer Experience Seal of Satisfaction. In addition to supplying the highest quality local anesthetics, Septodont now guarantees them! If these products do not produce a satisfactory customer experience, Septodont will provide the purchaser with a replacement box. Product must be purchased in the United States or Canada and be dated within the current shelf life. A satisfactory customer experience is defined as the product performing to the standard set forth in the Package Insert. All Septodont branded anesthetics are covered by the Guarantee, including:

• Septocaine® (articaine HCl and epinephrine) 1:100,000 (#01A1400) and 1:200,000 (#01A1200)
• Lignospan® Standard (lidocaine and epinephrine) 1:100,000 (#01A1100)
• Lignospan® Forte (lidocaine and epinephrine) 1:50,000 (US #01A1050)
• Scandonest® 3% Plain (mepivacaine HCl) (US #01A1003)
• Scandonest® 2%L (mepivacaine HCl and levonordefrin 1:20,000 (US #01A1002)
• Vivacaine® (bupivacaine HCl and epinephrine) (US #01A1600)
• OraVerse® (phentolamine mesylate) (#99210 and #99204)

Septocaine®, Vivacaine®, Lignospan® and Scandonest® are amide-type local anesthetics, and reactions to these products are characteristic of those associated with other amide-type local anesthetics. A major cause of reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, inadvertent intravascular injection or slow metabolic degradation. Dental practitioners and/or clinicians who employ local anesthetic agents should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Local anesthetic solutions that contain a vasoconstrictor should be used cautiously, especially in patients with impaired cardiovascular function or vascular disease. Septocaine and Vivacaine contain sodium metabisulfite and Lignospan and Scandonest 2%L contain potassium metabisulfite, sulfites that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Accidental intravascular injection may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Local anesthetics are capable of producing methemoglobinemia. The clinical signs of methemoglobinemia are cyanosis of the nail beds and lips, fatigue and weakness. If methemoglobinemia does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended. Please see the Package Inserts for prescribing information.

OraVerse® is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used. OraVerse is indicated for reversal of the soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years old or weighing less than 15 kg (33 lbs). In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.